


Years Ahead in HIV Prevention Research

Time to Market



Vaginal Ring
Dapivirine monthly

Multiple regulatory approvals

WHO guidelines

Multiple implementation science projects

Selected Global Fund procurement and programs

- Demonstrated modest efficacy
- Unclear demand & limited initial supply
- Initial price ~\$180 per year
- Oct 2023: PopCouncil licensed Kiara Health in SA to mfg.; volumes and prices unknown
- Opportunity to build market and platforms for vaginal rings



Long-Acting Injectables
Cabotegravir
One intramuscular injection (3ml) every 2 months

Multiple regulatory approvals

WHO guidelines

Multiple implementation science projects

Selected PEPFAR and Global Fund procurement and programs

- Demonstrated high efficacy
- Unclear demand & limited initial supply
- Initial LMIC price ~\$240/yr; in 2024 ~\$170/yr
- March 2023: MPP & ViiV licensed to 3 generics that need 7 years to market
- Opportunity to build market and platforms for injectables

Lenacapavir
Two subcutaneous injections (1.5ml each) every 6 months

Phase 3: PURPOSE 1 & 2

Phase 2: PURPOSE 3, 4, 5

Possible regulatory approvals

Possible product introduction



F/TAF daily

Phase 3: part of PURPOSE 1

Possible regulatory approvals

MK-8527 monthly

Phase 2a: MK-8527-07

Possible Phase 3
Possible Go/No-Go Decision for Phase 3 in Q1 2025



Dual Prevention Pill
Co-formulated TDF/FTC and ethinyl estradiol/levonorgestrel oral contraceptive pill daily

Pilot bioequivalence (BE) study

Pivotal BE

Possible regulatory approvals

Possible product introduction

Acceptability Study: HPTN 104